Literature DB >> 19890242

Dimebon as a potential therapy for Alzheimer's disease.

Rachelle S Doody1.   

Abstract

Excellent treatment for Alzheimer's disease remains an unmet medical need. Although current therapies improve patients' abilities compared to placebo and temporarily maintain performance above baseline on a number of outcome measures, additional therapies are needed to augment the benefits over baseline and to prolong these improvements.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19890242     DOI： 10.1017/s1092852900024913

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  5 in total

Review 1.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

2.  The rise and fall of Dimebon.

Authors:  Ilya Bezprozvanny
Journal:  Drug News Perspect       Date:  2010-10

Review 3.  Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Authors:  Paul S Aisen; Jeffrey Cummings; Lon S Schneider
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 4.  Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Authors:  R E Becker; N H Greig
Journal:  Curr Alzheimer Res       Date:  2010-11       Impact factor: 3.498

Review 5.  Nutrition and prevention of Alzheimer's dementia.

Authors:  Arun Swaminathan; Gregory A Jicha
Journal:  Front Aging Neurosci       Date:  2014-10-20       Impact factor: 5.750
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.